AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Axsome Stockholders and Encourages Investors to Contact the Firm
News provided byBragar Eagel & Squire
Apr 27, 2022, 9:00 PM ET
NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NASDAQ: AXSM) on behalf of Axsome stockholders. Our investigation concerns whether Axsome has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
Before the market opened on August 9, 2021, Axsome announced that the U.S. Food and Drug Administration (FDA) had identified deficiencies in their review of Axsome's New Drug Application (NDA) for AXS-05. The Company said it is attempting to learn the nature of the discrepancies in order to address them, but said the development may lead to a delay in the potential approval of AXS-05.
On this news shares of Axsome stock fell 40% in intraday trading.
If you purchased or otherwise acquired Axsome shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by email at firstname.lastname@example.org, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.